SPR® Therapeutics Reveals Long-term SPRINT® PNS Data and MONARCH™ Trial Update

Five abstracts featuring the SPRINT PNS System by SPR Therapeutics were showcased at the American Society of Pain & Neuroscience (ASPN) Annual Conference in Miami, drawing significant attention from prominent pain specialists. Among these, the study titled "Four-Year Follow Up from a Prospective, Multicenter Study of 60-day Medial Branch Nerve Stimulation for the Treatment of Chronic Axial Back Pain" was distinguished as a Top Abstract. Dr. Christopher Gilmore of the Carolinas Pain Institute presented the long-term follow-up data, revealing that more than two-thirds of participants (15 out of 22) experienced significant pain relief, averaging 4.7 years post-treatment.

Dr. Gilmore highlighted the impressive long-lasting effects of the SPRINT PNS treatment, noting that it provides substantial and durable pain relief, making a compelling case for its use as a short-term yet effective treatment option for chronic pain.

Another notable abstract, “Primary Endpoint Results From a Prospective Single-Arm Study of 60-Day Peripheral Nerve Stimulation Treatment Targeting the Occipital Nerves for Head Pain” by Dr. Jerry Gutierrez, showcased primary endpoint data from the MONARCH Case Series Study. This study, the first of its kind to evaluate 60-day PNS for headache pain, reported that 85 percent of participants (17 out of 20) experienced at least a 50 percent reduction in pain by the end of treatment.

Additional abstracts presented included:

- “Percutaneous PNS Used for Treatment of Chronic Shoulder Pain: A Multi-Center Retrospective Chart Review” by Aman et al., which found that 75 percent of patients (132 out of 176) experienced at least a 50 percent reduction in pain after the 60-day PNS treatment. Patients receiving Bimodal PNS® treatment, which targets both motor and sensory nerves, had the highest success rates.

- “Retrospective Review of 60-day Peripheral Nerve Stimulation in the Treatment of Complex Regional Pain Syndrome” by Patel et al., which reviewed over 400 patients with CRPS and found that 72 percent (306 out of 424) reported at least a 50 percent reduction in pain and/or an improvement in quality of life based on Patient Global Impression of Change (PGIC) scores.

- “Percutaneous Peripheral Nerve Stimulation Relieves Chronic Postoperative Pain and Improves Function After Total Knee Arthroplasty: Holistic Responders in a Double-blind, Placebo-controlled Randomized Controlled Trial” by Goree et al. demonstrated that a significantly larger proportion of participants treated with 60-day PNS achieved holistic improvements in pain relief, function, walking ability, and quality of life compared to those receiving placebo stimulation. These findings were published in the journal Neuromodulation.

The most common adverse events associated with the SPRINT PNS System include skin irritation and erythema. The clinical studies reported no serious or unanticipated adverse events, affirming the safety profile of the treatment.

The SPRINT PNS System, developed by SPR Therapeutics, represents a significant advancement in pain treatment. This 60-day therapy is designed to recondition the central nervous system, offering sustained relief from chronic pain without the need for permanent implants, nerve destruction, or the risk of addiction. The system is approved for use up to 60 days for various pain conditions, including chronic, intractable pain, post-surgical pain, and post-traumatic acute pain, and is viewed as a preferable alternative to invasive treatments.